[P1–045]: THE EFFECT OF 6 MONTHS’ DOSING ON THE RATE OF AMYLOID‐RELATED IMAGING ABNORMALITIES (ARIA) IN THE MARGUERITE ROAD STUDY

Greater Incidence in solanezumab-assigned subjects Nasal Congestion 9 (0.5) 22 (1.3) 0.018 Vitamin D Deficiency 9 (0.5) 22 (1.3) 0.017 Cholelithiasis 8 (0.5) 18 (1.1) 0.046 Chest Discomfort 5 (0.3) 14 (0.8) 0.036 Eye Infection 1 (0.1) 9 (0.5) 0.011 Arthropod Sting 1 (0.1) 7 (0.4) 0.032 Cardiac Failure Congestive 1 (0.1) 7 (0.4) 0.033 Rash Pruritic 1 (0.1) 7 (0.4) 0.033 Eye Inflammation 0 (0.0) 6 (0.4) 0.014 Breast Mass 0 (0.0) 4 (0.2) 0.044 Emphysema 0 (0.0) 4 (0.2) 0.044 Greater Incidence in placebo-assigned subjects Urinary Incontinence 39 (2.3) 23 (1.3) 0.045 Gait Disturbance 24 (1.4) 9 (0.5) 0.010 Somnolence 27 (1.6) 8 (0.5) 0.001 Epistaxis 22 (1.3) 8 (0.5) 0.011 Hyponatraemia 19 (1.1) 6 (0.4) 0.010 Subdural Haematoma 13 (0.8) 3 (0.2) 0.013 Upper Limb Fracture 11 (0.6) 3 (0.2) 0.034 Intervertebral Disc Degeneration 11 (0.6) 2 (0.1) 0.013 Behavioural and Psychiatric Symptoms of Dementia 7 (0.4) 1 (0.1) 0.035